Fat cells allow melanoma cells to penetrate the dermis, from which they spread, causing fatal metastases in vital organs, TAU researchers say
Researchers at Tel Aviv University, led by Prof. Carmit Levy and Dr. Tamar Golan of the Department of Human Genetics and Biochemistry at TAU’s Sackler School of Medicine, have discovered that fat cells are involved in the transformation that melanoma cells undergo from cancer cells of limited growth in the epidermis to lethal metastatic cells attacking patients’ vital organs.
“We have answered a major question that has preoccupied scientists for years,” explains Prof. Levy. “What makes melanoma change form, turning aggressive and violent? Locked in the skin’s outer layer, the epidermis, melanoma is very treatable; it is still Stage 1, it has not penetrated the dermis to spread through blood vessels to other parts of the body and it can simply be removed without further damage.
“Melanoma turns fatal when it ‘wakes up,’ sending cancer cells to the dermis layer of skin, below the epidermis, and metastasizing in vital organs. Blocking the transformation of melanoma is one of the primary targets of cancer research today, and we now know fat cells are involved in this change.””
The research was conducted in collaboration with several senior pathologists: Dr. Hanan Vaknin of Wolfson Medical Center, and Dr. Dov Hershkowitz and Dr. Valentina Zemer of Tel Aviv Medical Center.
The study was on published July 23 in Science Signaling and is featured on the journal’s cover.
In the study, the researchers examined dozens of biopsy samples taken from melanoma patients at Wolfson Medical Center and Tel Aviv Medical Center, and observed a suspicious phenomenon: fat cells near the tumor sites.
“We asked ourselves what fat cells were doing there and began to investigate,” adds Prof. Levy. “We placed the fat cells on a petri dish near melanoma cells and followed the interactions between them.”
The researchers observed fat cells transferring proteins called cytokines, which affect gene expression, to the melanoma cells.
“Our experiments have shown that the main effect of cytokines is to reduce the expression of a gene called miRNA211, which inhibits the expression of a melanoma receptor of TGF beta, a protein that is always present in the skin,” says Prof. Levy. “The tumor absorbs a high concentration of TGF beta, which stimulates melanoma cells and renders them aggressive.”
Critically, the researchers have also found a way to block this transformation.
“It is important to note that we found the process reversible in the laboratory: When we removed the fat cells from the melanoma, the cancer cells calmed down and stopped migrating,” adds Prof. Levy.
A trial of mouse models of melanoma yielded similar results: When miRNA211 was repressed, metastases were found in other organs, while re-expressing the gene blocked metastases formation.
In the search for a potential drug based on the new discovery, the researchers experimented with therapies that are known to inhibit cytokines and TGF beta, but which have never before been used to treat melanoma.
“We are talking about substances that are currently being studied as possible treatments for pancreatic cancer, and are also in clinical trials for prostate, breast, ovarian and bladder cancers,” Dr. Golan said. “We saw that they restrained the metastatic process, and that the melanoma returned to its relatively ‘calm’ and dormant state.”
“Our findings can serve as a basis for the development of new drugs to halt the spread of melanoma — therapies that already exist, but were never used for this purpose,” concludes Prof. Levy. “In the future, we are seeking to collaborate with drug companies to enhance the development of the metastatic melanoma prevention approach.”
The Latest on: Melanoma
via Google News
The Latest on: Melanoma
- PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1on March 4, 2021 at 11:39 pm
Metabolic deregulation, a hallmark of cancer, fuels cancer cell growth and metastasis. Here, we show that phosphoserine phosphatase (PSPH), an enzyme of the serine metabolism pathway, is upregulated ...
- Circulating T Cells Provide Insight on Tumor Sister Cells in Advanced Melanomaon March 4, 2021 at 4:00 pm
A new study found that performing single-cell RNA sequencing on T cells circulating in the blood provided significant insight on sister cells within tumor tissue in advanced melanoma.
- Knocking out alpha-synuclein in melanoma cells dysregulates cellular iron metabolism and suppresses tumor growthon March 4, 2021 at 9:07 am
The protein alpha-synuclein (α-syn) is unusual because, depending on its conformation and the type of cell in which it is expressed, it is pro-death or pro-survival, triggering neurodegeneration in ...
- A simple blood draw may help discover tumor reactive immune cells to treat advanced melanomaon March 2, 2021 at 5:07 pm
According to a new study led by Yale Cancer Center and Department of Neurology researchers, a simple blood draw may be the first step in helping to discover tumor reactive immune or T cells to treat ...
- Highlight & Pivotal start Phase IIa melanoma trialon March 2, 2021 at 4:08 am
Highlight Therapeutics and Pivotal work together on Melanoma therapy andlaunch a Phase IIa trial to examine BO-112 efficacy and safety Trial will examine administration of Highlight's BO-112 in ...
- Melanoma Resistance to Checkpoint Therapy Scrutinized with Perturb-CITE-Seqon March 1, 2021 at 4:00 pm
Multimodal single-cell analysis was used to survey pathways used by melanoma to defy checkpoint inhibitor therapy and escape the immune system.
- Why some melanoma patients do not respond to immunotherapyon March 1, 2021 at 12:45 pm
The researchers tested their new technique with cancer cells and matching immune cells from melanoma patients and identified previously unknown resistance mechanisms to immune checkpoint ...
- Melanoma Institute Australia launches digital campaign of flagship fundraiseron March 1, 2021 at 8:12 am
Melanoma Insitute Australia has launched a digital form of its flagship fundraising campaign, Melanoma March.The announcement:Not-for-profit organisation Melanoma Institute Australia (MIA) has ...
- Global Intraocular Melanoma Treatment Market is expected to grow steadily grow at CAGR of 7.9% in the Forecast Period of 2021-2026on February 27, 2021 at 7:47 am
For a snapshot of the primary and secondary data of the market (2015-2025), along with business strategies and detailed market segmentation, please click on the request sample report. The sample ...
- Top 10 Risk Factors Of Melanoma And How To Prevent Iton February 27, 2021 at 6:03 am
In partnership with The Fresh Toast Researchers are committed to gaining more information about melanoma, its potential causes, and ways people can protect themselves against this type of cancer. Do ...
via Bing News